Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. After winning a broader FDA label in metastatic castration-resistant prostate cancer (mCRPC) ...
The 2026 SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kiflom Gebreslassea discussing a longitudinal analysis of estimated glomerular filtration rate ...
(UroToday.com) The 2026 SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Bryce Tan discussing a study assessing the efficacy of immunological priming of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results